HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography

The case for adopting HeartFlow FFR_CT for estimating fractional flow reserve from coronary CT angiography (CCTA) is supported by the evidence. The technology is non-invasive and safe, and has a high level of diagnostic accuracy.

HeartFlow FFR_CT should be considered as an option for patients with stable, recent-onset chest pain who are offered CCTA in line with the NICE guideline on chest pain. Using HeartFlow FFR_CT may avoid the need for invasive coronary angiography and revascularisation. For correct use, HeartFlow FFR_CT requires access to 64‑slice (or above) CCTA facilities.

Based on the current evidence and assuming there is access to appropriate CCTA facilities, using HeartFlow FFR_CT may lead to cost savings of £391 per patient [2021]. By adopting this technology, the NHS in England may save a minimum of £9.4 million by 2022 through avoiding invasive investigation and treatment [2021].